While current therapeutic options include chemotherapy and immunotherapy, this study opens new avenues for novel approaches ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

there was much anticipation around the latest results of the phase 1b/2 CARTITUDE-1 clinical trial which assessed ciltacabtagene autoleucel (cilta-cel), the investigational B cell maturation ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

When your doctor talks to you about your B-cell lymphoma, they'll tell you what type you have. It's an important piece of info to get, because each type of this cancer acts differently and has its ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

like B-cell maturation antigen (BCMA) — a target in multiple myeloma — have also entered the discussion, according to Calabrese. “If we are accomplishing remission with CD19, do we need BCMA?” ...